Resona Pharmaceutical Limited, a active public limited company, was established on 23 March 2021 in Salem, Tamil Nadu, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U33110TZ2021PLC035879. Registered under ROC Roc Coimbatore. it is unlisted. It has an authorized capital of ₹1.00 M and a paid-up capital of ₹0.10 M.
Its leadership includes Senthilvelan Durisamy (Additional Director), Kuppuraj Shanmugavadivu (Director), Duraisami Sathishkannan (Director). Past directors included Suresh Babu Roshan Vijay. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at 253/8, Arun Nagar Annexe, Iyer Thottam, Periyapuddur,, Salem, Tamil Nadu, 636016.
U33110TZ2021PLC035879
035879
23 March 2021
₹1.00 M
₹0.10 M
Roc Coimbatore
Unlisted
Active
Explore comprehensive insights into Resona Pharmaceutical Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Senthilvelan Durisamy | Additional Director | 01 Oct 2024 | Current |
| Kuppuraj Shanmugavadivu | Director | 23 Mar 2021 | Current |
| Duraisami Sathishkannan | Director | 23 Mar 2021 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 01 Oct 2024 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Resona Pharmaceutical Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 29.54% increase. The company also saw a substantial improvement in profitability, with a 314.92% increase in profit. The company's net worth Soared by an impressive increase of 119.74%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Resona Pharmaceutical had a promoter holding of 60.00% and a public holding of 40.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Resona Pharmaceutical has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Resona Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Resona Pharmaceutical's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Senthilvelan Durisamy was appointed as a Additional Director was appointed as a Additional Director on 01 Oct 2024 & has been associated with this company since 1 year 3 months . was recorded as a recent event.
The activity Resona Pharmaceutical Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was completed.
Resona Pharmaceutical Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Coimbatore. was recorded as a recent event.
The activity Kuppuraj Shanmugavadivu was appointed as a Director was appointed as a Director on 23 Mar 2021 & has been associated with this company since 4 years 9 months . was completed.
The activity Duraisami Sathishkannan was appointed as a Director was appointed as a Director on 23 Mar 2021 & has been associated with this company since 4 years 9 months . was completed.
Resona Pharmaceutical Limited was registered on 23 Mar 2021 with Roc Coimbatore & aged 4 years 9 months as per MCA records. was recorded as a recent event.
The CIN of Resona Pharmaceutical Limited is U33110TZ2021PLC035879.
Resona Pharmaceutical Limited is headquartered at 253/8, Arun Nagar Annexe, Iyer Thottam, Periyapuddur,, Salem, Tamil Nadu, 636016.
Resona Pharmaceutical Limited was incorporated on 23 March 2021.
The current directors of Resona Pharmaceutical Limited are
The primary industry of Resona Pharmaceutical Limited is Manufacturing.
Resona Pharmaceutical Limited is unlisted.
The authorized capital of Resona Pharmaceutical Limited is ₹1.00 M, and the paid-up capital is ₹0.10 M.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX